Extracellular targeted drug conjugates
The present invention relates to, inter alia, extracellular drug conjugates (EDC) in which an antibody or other targeting agent (e.g. a targeting moiety) is linked to a drug through a linker (e.g. a non-cleavable linker). These conjugates are useful in the treatment of disease and/or as a tool in the evaluation of biological systems.
1. A drug conjugate comprising an antibody that specifically binds human ATPase subunit gamma 5 covalently linked to a cardiac glycoside via a polyethylene glycol linker composed of from twelve to forty-four ethylene groups, wherein said cardiac glycoside is selected from the group consisting of: CEN09-106 (scillarenin-4-amino-4-deoxy-L-xylopyranoside), CEN08-243 ((3S)-3-N-methoxyamino-scillarenin-L-neo-4-amino-4-deoxyxyloside), and CEN09-107 (scillarenin-4-amino-4-deoxy-L-ribopyranoside).